Status Unknown
Active Pharmacovigilance Study of the Medicine Rinvoq Upadacitinib
Led by Universidade do Porto · Updated on 2024-07-15
150
Participants Needed
3
Research Sites
8 weeks
Total Duration
On this page
Sponsors
U
Universidade do Porto
Lead Sponsor
I
INFARMED - Autoridade Nacional do Medicamento e Produtos de Saúde, I.P.
Collaborating Sponsor
AI-Summary
What this Trial Is About
The LOOK-UP is an investigator-initiated clinical study with the aim of monitoring the post-marketing safety of the medicine Rinvoq™ (upadacitinib), which is indicated for the treatment of rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis, atopic dermatitis, ulcerative colitis, and Crohn's disease. The Marketing Authorisation Holder is AbbVie Deutschland GmbH \& Co. KG.
CONDITIONS
Brief Title
Active Pharmacovigilance Study of the Medicine Rinvoq™ (Upadacitinib)
Who Can Participate
Eligibility Criteria
Inclusion Criteria:
- Prescription of Rinvoq™ from January 1, 2024;
- 18 years of age or older at the time of recruitment; and
- Expressed consent to participate in the study.
Exclusion Criteria:
- They have any degree of cognitive impairment that prevents them from responding to a questionnaire administered by telephone;
- They are participating in a phase I, II, or III clinical trial;
- They have a life expectancy of less than 1 month; or
- They do not have a valid telephone contact.
Research Team
I
Inês Ribeiro Vaz, PharmD, MPH, PhD
R
Renato Ferreira da Silva, PharmD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here